WINTON GROUP Ltd Sells 1,675 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ)

WINTON GROUP Ltd lowered its position in Jazz Pharmaceuticals (NASDAQ:JAZZ) by 44.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,070 shares of the specialty pharmaceutical company’s stock after selling 1,675 shares during the quarter. WINTON GROUP Ltd’s holdings in Jazz Pharmaceuticals were worth $279,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. US Bancorp DE lifted its position in shares of Jazz Pharmaceuticals by 49.5% during the 4th quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock worth $147,000 after buying an additional 360 shares during the last quarter. Advisor Group Inc. lifted its position in shares of Jazz Pharmaceuticals by 62.4% during the 3rd quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock worth $210,000 after buying an additional 550 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Jazz Pharmaceuticals by 795.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,746 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 1,551 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Jazz Pharmaceuticals by 29.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock worth $257,000 after buying an additional 400 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $291,000. Institutional investors own 91.20% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of JAZZ opened at $149.91 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.15 and a current ratio of 3.29. The firm has a market capitalization of $8,981.27, a price-to-earnings ratio of 15.68, a PEG ratio of 0.78 and a beta of 0.97. Jazz Pharmaceuticals has a 1 year low of $128.58 and a 1 year high of $163.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.73 by ($0.15). The firm had revenue of $436.40 million during the quarter, compared to analyst estimates of $440.91 million. Jazz Pharmaceuticals had a net margin of 30.14% and a return on equity of 22.63%. equities research analysts expect that Jazz Pharmaceuticals will post 11.48 EPS for the current year.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 3,000 shares of the business’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $150.00, for a total value of $450,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $148.65, for a total transaction of $29,730.00. Following the completion of the transaction, the executive vice president now directly owns 21,669 shares in the company, valued at $3,221,096.85. The disclosure for this sale can be found here. Insiders sold a total of 13,758 shares of company stock worth $2,031,181 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

Several analysts have recently weighed in on JAZZ shares. Cantor Fitzgerald restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Sunday, December 10th. B. Riley restated a “buy” rating and set a $206.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 20th. Wells Fargo restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 25th. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Finally, Leerink Swann began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $180.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $180.78.

WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/winton-group-ltd-has-279000-stake-in-jazz-pharmaceuticals-plc-jazz.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply